MedPath

Comparing Two Medicines for Healing Jaw Bone Infections After Root Canal Treatment

Not Applicable
Not yet recruiting
Conditions
Periapical Periodontitis
Periapical Lesion
Interventions
Registration Number
NCT07239739
Lead Sponsor
Faiz ur rahman
Brief Summary

This study compares two commonly used intracanal medicaments-Triple Antibiotic Paste and Calcium Hydroxide-in patients with infected single-rooted teeth. The purpose is to determine which medicament promotes faster healing of periapical lesions after root canal treatment by measuring reduction in lesion size and improvement in bone density over 3, 6, and 12 months.

Detailed Description

This single-center, parallel-arm, randomized controlled trial aims to directly compare the efficacy of Triple Antibiotic Paste (TAP) and Calcium Hydroxide (CH) as intracanal medicaments on the rate of healing of periapical lesions in single-rooted teeth. Systemically healthy adults (18-65 years) with a diagnosis of pulpal necrosis and asymptomatic apical periodontitis or chronic apical abscess, presenting with a radiographically evident periapical radiolucency (≥2mm), will be enrolled. Following informed consent, chemomechanical preparation, and randomization, participants will receive either TAP (Ciprofloxacin:Metronidazole:Minocycline) or CH as the intracanal medicament. The primary outcome is the rate of healing, quantified by the percentage reduction in periapical lesion area and improvement in bone density scores assessed on standardized periapical radiographs or CBCT scans at 3, 6, and 12-month follow-ups. Secondary outcomes include clinical resolution (absence of pain, tenderness, sinus tract) and radiographic resolution (restoration of normal periapical architecture). Data will be analyzed using intention-to-treat analysis, with repeated-measures ANOVA to compare healing trajectories between groups.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
62
Inclusion Criteria
  • Systemically healthy adult patients between 18 and 65 years of age.

Presence of a single-rooted tooth diagnosed with pulpal necrosis and asymptomatic apical periodontitis or chronic apical abscess.

Radiographic evidence of a distinct periapical radiolucency with a minimum diameter of 2mm.

The involved tooth must be deemed restorable after endodontic treatment.

Patient willingness and ability to provide informed consent and comply with the follow-up schedule

Exclusion Criteria

Patients under 18 or over 65 years of age.

Presence of systemic diseases known to affect bone metabolism or immune response (e.g., uncontrolled diabetes).

Pregnancy or lactation.

Known allergies to any components of Triple Antibiotic Paste or calcium hydroxide.

Teeth with previous root canal treatment, internal/external root resorption, root fractures, or non-endodontic periapical pathology.Exclusion Criteria:

-

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Triple Antibiotic Paste (TAP)Triple Antibiotic PasteTAP placed as intracanal medicament following chemo-mechanical preparation; temporary restoration maintained for several weeks
Calcium Hydroxide GroupCalcium Hydroxide (Ca(OH)2)Calcium Hydroxide intracanal dressing placed following chemo-mechanical preparation; sealed temporarily
Triple Antibiotic Paste (TAP)Calcium Hydroxide (Ca(OH)2)TAP placed as intracanal medicament following chemo-mechanical preparation; temporary restoration maintained for several weeks
Calcium Hydroxide GroupTriple Antibiotic PasteCalcium Hydroxide intracanal dressing placed following chemo-mechanical preparation; sealed temporarily
Primary Outcome Measures
NameTimeMethod
Change in Periapical Lesion AreaBaseline, 3 months, 6 months, 12 months

Percentage reduction in the area (mm²) of the periapical radiolucency from baseline, as measured on standardized periapical radiographs or CBCT scans.

Secondary Outcome Measures
NameTimeMethod
Change in Periapical Bone Density ScoreBaseline, 3 months, 6 months, 12 months

Improvement in a standardized bone density score or grayscale value of the periapical bone from baseline

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.